Dorzagliatin is an investigational drug.
There have been 7 clinical trials for Dorzagliatin.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2022.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Glucose Intolerance, and Diabetes Mellitus. The leading clinical trial sponsors are Hua Medicine Limited, Chinese University of Hong Kong, and University of Virginia.
There are two US patents protecting this investigational drug and fifty-two international patents.